Drug Trial Radar · NCT01929226
Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
Last checked: Nov 20, 2026Latest source record: Apr 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
280
Actual
Start
Jul 9, 2013
Primary completion
Nov 29, 2013
Study completion Nov 29, 2013
Sponsor
- Lead sponsor
- Elusys TherapeuticsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 27, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability and pharmacokinetics (PK) of a single intravenous (IV) dose of ETI-204 in adult volunteers.
Conditions
- Inhalational Anthrax
Interventions
ETI-204Biological
Monoclonal Antibody
PlaceboOther
Placebo for ETI-204
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Adverse EventsTime frame: Up to 71 days or 101 days (30 days after the final study visit) for subjects with ongoing adverse events at the final study visit, for each group.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Inc.
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.